New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMVa??s DPX-Survivac in Combination with Mercka??s Keytruda in Patients with DLBCL

IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology
corporation, today announced updated data from the ongoing
investigator-sponsored SPiReL Phase 2 clinical trial assessing IMVa??s
lead candidate, DPX-Survivac, in combination with intermittent low dose
cyclophosphamide and Mercka??s checkpoint inhibitor KeytrudaA®
(pembrolizumab). The trial is designed to evaluate the safety and
efficacy of the combination immunotherapy in patients with persistent or
recurrent/refractory diffuse large B-cell lymphoma (DLBCL).

At the first "on treatmenta?? assessment, five of the first six patients
demonstrated clinical benefit, including four patients with tumor
regressions. Two patients reached a complete radiological response, one
a partial response, and two had stable disease while on study. In
addition, the combination continued to demonstrate an acceptable safety

"We are highly encouraged by the level of activity that we are observing
with the combination of DPX-Survivac and Keytruda in these patients with
DLBCL,a?? said Frederic
Ors, IMVa??s Chief Executive Officer. "We believe that the clinical
benefits the SPiReL trial has yielded thus far, and the data linking
this antitumor activity with the T cell responses, support
DPX-Survivaca??s novel mechanism of action and our combination
immunotherapy approach. We will continue working with our partners to
advance this clinical study towards improving the lives of patients with
difficult-to-treat cancers who need better treatment options.a??

Updated SPiReL Data Highlights:

At the time of data cut-off for this analysis, 11 patients were enrolled
in the trial. Efficacy data from the first six evaluable patients are
based on modified Cheson criteriai:
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »